EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data: a Delphi approach

Rajendran, Nithya; Arieti, Fabiana; Mena-Benítez, Carla Alejandra; Galia, Liliana; Tebon, Maela; Álvarez, Julio; Gladstone, Beryl Primrose; Collineau, Lucie; Angelis, Giulia De; Duro, Raquel; Gaze, William; Göpel, Siri; Kanj, Souha S.; Käsbohrer, Annemarie; Limmathurotsakul, Direk; Abechuco, Estibaliz Lopez de; Mazzolini, Elena; Mutters, Nico T.; Pezzani, Maria Diletta; Presterl, Elisabeth; Renk, Hanna; Rodríguez‐Baño, Jesús; ̆andulescu, Oana S; Scali, Federico; Skov, Robert; Velavan, Thirumalaisamy P.; Vuong, Cuong; Tacconelli, Evelina; group, on behalf of the EPI-Net One Health consensus working

doi:10.1016/j.lanepe.2022.100563

Cited by 10 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A One Health approach to report AMR using the Delphi method has been proposed [288]. This Delphi method states that there must be strategic and standardised ways of reporting surveillance data which must be used to monitor AMR, provide interventional measures, and inform policy [288].…”

Section: One Health Concept For Surveillance and Management Of Amrmentioning

confidence: 99%

Global Strategies to Combat Antimicrobial Resistance: A One Health Perspective

Mudenda,

Chabalenge,

Daka

et al. 2023

View full text Add to dashboard Cite

Background: Antimicrobial resistance (AMR) is a global health challenge that has escalated due to the inappropriate use of antimicrobials in humans, animals, and the environment. Developing and implementing strategies to reduce and combat AMR is critical. Purpose: This study aimed to highlight some global strategies that can be implemented to address AMR using a One Health approach. Methods: This study employed a narrative review design that included studies published from January 2002 to July 2023. The study searched for literature on AMR and antimicrobial stewardship (AMS) in PubMed and Google Scholar using the 2020 PRISMA guidelines. Results: This study reveals that AMR remains a significant global public health problem. Its severity has been markedly exacerbated by inappropriate use of antimicrobials in humans, animals, and the broader ecological environment. Several strategies have been developed to address AMR, including the Global Action Plan (GAP), National Action Plans (NAPs), AMS programs, and implementation of the AWaRe classification of antimicrobials. These strategies also involve strengthening surveillance of antimicrobial consumption and resistance, encouraging the development of new antimicrobials, and enhancing regulations around antimicrobial prescribing, dispensing, and usage. Additional measures include promoting global partnerships, combating substandard and falsified antimicrobials, advocating for vaccinations, sanitation, hy-How to cite this paper:

show abstract

Section: One Health Concept For Surveillance and Management Of Amrmentioning

confidence: 99%

Global Strategies to Combat Antimicrobial Resistance: A One Health Perspective

Mudenda,

Chabalenge,

Daka

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This study also highlights the significance of integrated surveillance of AMR which encompasses integration and analysis of both AMR and AMC surveillance data at the one health interface [ 51 , 89 , 105 ]. Analysis of both AMR and AMC data provides more insight into the trends of AMR, and the impact of AMC on AMR which improves policy action and planning for AMS programs [ 106 ]. Although our study focuses on only human AMC and AMR data, integrating and analyzing AMC and AMR in the One Health interface is very critical to properly understanding the drivers of AMR [ 31 ], and studies have established that AMC and AMR in animals and environment could also drive AMR in humans [ 38 , 107 ].…”

Section: Discussionmentioning

confidence: 99%

Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries

Ajulo,

Awosile

2024

PLoS ONE

View full text Add to dashboard Cite

For the first time since 2015, the World Health Organization’s (WHO) global Antimicrobial Resistance and Use Surveillance (GLASS) featured both global reports for antimicrobial resistance (AMR) and antimicrobial consumption (AMC) data in its annual reports. In this study we investigated the relationship of AMR with AMC within participating countries reported in the GLASS 2022 report. Our analysis found a statistically significant correlation between beta-lactam/cephalosporin and fluoroquinolones consumption and AMR to these antimicrobials associated with bloodstream E. coli and Klebsiella pneumoniae among the participating countries (P<0.05). We observed that for every 1 unit increase in defined daily dose DDD of beta-lactam/cephalosporins and quinolone consumptions among the countries, increased the recoveries of bloodstream-associated beta-lactam/cephalosporins-resistant E. coli/Klebsiella spp. by 11–22% and quinolone-resistant E. coli/Klebsiella spp. by 31–40%. When we compared the antimicrobial consumptions between the antimicrobial ATC (Alphanumeric codes developed by WHO) groups and countries, we observed a statistically significant higher daily consumption of beta-lactam-penicillins (J01C, DDD difference range: 5.23–8.13) and cephalosporins (J01D, DDD difference range: 2.57–5.13) compared to other antimicrobial groups among the countries (adjusted for multiple comparisons using Tukey’s method). Between the participating countries, we observed a statistically significant higher daily consumption of antimicrobial groups in Iran (DDD difference range: 3.63–4.84) and Uganda (DDD difference range: 3.79–5.01) compared to other participating countries (adjusted for multiple comparisons using Tukey’s method). Understanding AMC and how it relates to AMR at the global scale is critical in the global AMR policy development and implementation of global antimicrobial stewardship.

show abstract

“…The EPI-Net consortium plays a crucial role in advancing the understanding of antibiotic resistance within the context of genomic surveillance and One Health. The consortium recently developed a reporting guideline [176], with the objective of standardising data collection and reporting in the context of antimicrobial consumption and resistance surveillance within the One Health framework. This standardisation is vital for tracking the spread of antimicrobial resistance and evaluating the impact of interventions.…”

Section: One Health Genomics and Perspectivesmentioning

confidence: 99%

Current Uses and Future Perspectives of Genomic Technologies in Clinical Microbiology

Bianconi,

Aschbacher,

Pagani

2023

Antibiotics

View full text Add to dashboard Cite

Recent advancements in sequencing technology and data analytics have led to a transformative era in pathogen detection and typing. These developments not only expedite the process, but also render it more cost-effective. Genomic analyses of infectious diseases are swiftly becoming the standard for pathogen analysis and control. Additionally, national surveillance systems can derive substantial benefits from genomic data, as they offer profound insights into pathogen epidemiology and the emergence of antimicrobial-resistant strains. Antimicrobial resistance (AMR) is a pressing global public health issue. While clinical laboratories have traditionally relied on culture-based antimicrobial susceptibility testing, the integration of genomic data into AMR analysis holds immense promise. Genomic-based AMR data can furnish swift, consistent, and highly accurate predictions of resistance phenotypes for specific strains or populations, all while contributing invaluable insights for surveillance. Moreover, genome sequencing assumes a pivotal role in the investigation of hospital outbreaks. It aids in the identification of infection sources, unveils genetic connections among isolates, and informs strategies for infection control. The One Health initiative, with its focus on the intricate interconnectedness of humans, animals, and the environment, seeks to develop comprehensive approaches for disease surveillance, control, and prevention. When integrated with epidemiological data from surveillance systems, genomic data can forecast the expansion of bacterial populations and species transmissions. Consequently, this provides profound insights into the evolution and genetic relationships of AMR in pathogens, hosts, and the environment.

show abstract

EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data: a Delphi approach

Cited by 10 publications

References 17 publications

Global Strategies to Combat Antimicrobial Resistance: A One Health Perspective

Global Strategies to Combat Antimicrobial Resistance: A One Health Perspective

Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries

Current Uses and Future Perspectives of Genomic Technologies in Clinical Microbiology

Contact Info

Product

Resources

About